Table 4.

In silico Validation of the Endoplasmic Reticulum Stress Phenotype, Taking Into Account Previous Experimental And Clinical Reports

Reference	Array platform	Description of sample	Gene signature	Match to present study
26	Agilent 24479 60-mer oligos	97 Samples from LN− patients	231 Prognosis reporters (risk of distant metastasis)	0
			430 Brca1 reporters	3 (EEF1D, MCM4, RPL5)
			2460 ER− reporters	3 (CLN3, MCM4, RPS12)
30	Rosetta inkjet (24479 genes; breast adenocarcinoma) oligonucleotide microarray	279 Primary tumors of diverse types (lung, breast, prostate)	128 Genes able to distinguish patients with good versus poor prognosis	0
27	Multiple gene expression signatures “metagenes”	86 LN+ breast cancer patients	143 Predictors of lymph node metastasis	0
			165 Predictors of breast cancer recurrence	2 (FAM3A, TBCD)
28	Affymetrix U133A 25-mer oligos	LN− and LN+ patients with invasive breast cancer	76-Gene signature to distinguish LN− primary breast cancer to develop distant metastasis within 5 years	0
33	Affymetrix U133A	82 Breast cancer patients (primary tumors)	95 Genes predictors of lung metastasis	0
31	Agilent 24479 60-mer oligos	161 Patients in stage I and II breast cancer with age <53 years	70-Gene predictor of local recurrence	0
29	Agilent 22575 60-mer oligos	135 Tumor samples (no criteria for selection)	70-Gene prognostic signature (risk of metastasis)	0
32	Operon 70-mer two-color 21239 probes	35 Patients: primary tumor and lymph node metastasis paired samples	79 Differentially expressed genes between primary samples and metastasis samples	0
35	Affymetrix U133A	8 Bone metastases, 18 brain metastases and 3 primary tumors	51 Brain metastasis specific genes (versus bone metastasis)	1 (GFAP)
19	Affymetrix U133A	CN34-BrM2 and MDA231-BrM2 brain metastatic cell lines.	17 Genes whose expression was correlated with brain relapse	0
		368 Breast cancer primary tumors	26 Genes whose expression was increased in brain metastatic cell lines but not in bone or lung metastatic cell lines	0

LN, lymph node.